U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177794) titled 'Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC' on Sept. 10.
Brief Summary: Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory. More importantly, there is a lack of effective consolidation treatment after CRT, resulting in a high recurrence rate. Our previous prospective phase II trial (EC-CRT-001) demonstrated that the addition of toripalimab to definitive CRT improved the complete response rate in patients with locally advanced esophageal squamous cell carcinoma (ESCC), showing potential for enhanc...